Cancer Therapy Advisor

4 days ago | cancertherapyadvisor.com | Jen Smith

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances that may inform the treatment of gastrointestinal cancer.1-8 Read on for more details on these studies. Results from the phase 3 MATTERHORN trial support perioperative durvalumab plus FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) as a new standard of care for patients with localized gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to Yelena Y.

5 days ago | cancertherapyadvisor.com | Erin Clancy

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in lung cancer as well as treatments that fell short of expectations.1-6 Read on for more details on these studies. Results from the phase 3 DeLLphi-304 trial support tarlatamab as a “preferable” second-line therapy for patients with small cell lung cancer (SCLC), according to Charles M.

6 days ago | cancertherapyadvisor.com | Erin Clancy

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances that may inform the treatment of breast cancer.1-10 Read on for more details on these studies.

6 days ago | cancertherapyadvisor.com | Jessica Nye

Adding tafasitamab to treatment with lenalidomide and rituximab can improve responses and progression-free survival (PFS) in patients with relapsed or refractory follicular lymphoma (FL), according to research presented at the 18th International Conference on Malignant Lymphoma.1  These results, from the phase 3 inMIND trial, suggest that tafasitamab plus lenalidomide and rituximab may represent a new standard of care for this patient population, said study presenter Laurie H.

1 week ago | cancertherapyadvisor.com | Jessica Nye

Ropeginterferon alfa-2b proved more effective than anagrelide in a phase 3 trial of patients with high-risk essential thrombocythemia (ET) who were resistant or intolerant to hydroxyurea. Results from this trial were presented at the EHA 2025 Congress. The trial, SURPASS-ET (NCT04285086), included 174 patients with high-risk ET who were resistant or intolerant to hydroxyurea. The patients were randomly assigned to receive either ropeginterferon alfa-2b (n=91) or anagrelide (n=83) for 52 weeks.